Extracorporeal Shock Wave Therapy (ESWT) for the Treatment of Spasticity in Persons With Spinal Cord Injury

Sponsor
Swiss Paraplegic Centre Nottwil (Other)
Overall Status
Completed
CT.gov ID
NCT02203994
Collaborator
(none)
20
1
1
29
0.7

Study Details

Study Description

Brief Summary

Spasticity is the most problematic self-reported secondary medical problem in patients with spinal cord injury. It has the potential to negatively influence quality of life through restricting activities of daily living. Problematic spasticity can cause pain and fatigue, disturb sleep, contribute to the developement of contractures and pressure ulcers, and has a negative effect on patients morbidity. For this reason there is enormous interest in therapeutic interventions addressing to decrease spasticity in persons with spinal cord injury. Recently, studies reported positive effects of extracorporeal shock wave therapy on spasticity in patients with stroke, focal limb dystonia and cerebral palsy. To date, no studies are published, assessing the effect of extracorporeal shock wave therapy on focal spasticity in patients with spinal cord injury.

The purpose of this study is to investigate the effect of a one-time ESWT on lower limb spasticity in patients with an incomplete spinal cord injury.

Condition or Disease Intervention/Treatment Phase
  • Device: Duolith® SD 1 "T-Top" (Storz Medical AG, Switzerland)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effect of Extracorporeal Shock Wave Therapy (ESWT) on Lower Limb Spasticity in Persons With an Incomplete Spinal Cord Injury
Actual Study Start Date :
Jul 1, 2014
Actual Primary Completion Date :
Oct 1, 2016
Actual Study Completion Date :
Dec 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: extracorporeal shock wave therapy (ESWT)

one-time treatment of the spastic muscle/ spastic muscles (adductor muscles and/ or M. triceps surae) with extracorporeal shock wave therapy (device: Duolith® SD 1 "T-Top" (Storz Medical AG, Tägerwilen, Switzerland))

Device: Duolith® SD 1 "T-Top" (Storz Medical AG, Switzerland)
2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz

Outcome Measures

Primary Outcome Measures

  1. severity of spasticity [time 0, time 2h]

    Ashworth Scale

Secondary Outcome Measures

  1. personal goal attainment [at day 0, 1, 3 and 5]

    Goal Attainment Scale

  2. walking speed [difference between pre- and post-intervention]

    10 Meters Walking Test

  3. walking distance [difference between pre- and post-intervention]

    6 Minutes Walking Test

  4. thickness of the treated muscle [difference between pre- and post-intervention]

    thickness measurement of the treated muscle using ultrasound

  5. severity of spasticity [time 0, time 2h]

    Adductor Tone Rating Scale

  6. severity of spasticity [time 0, time 2h]

    Penn Spasm Frequency Scale

  7. severity of spasticity [time 0, time 2h]

    Clonus Scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Traumatic or non traumatic spinal cord injury

  • Minimum age: 18 years

  • Minimum time since spinal cord injury: two years

  • Lesion: C3-Th10

  • American Association of Spinal Cord Injury Impairment Score C and D

  • Focal spasticity in the adductor muscles and/ or triceps surae

  • Ability to walk 14 meters

  • Spasticity/clonus/spasms disturbing the activities of daily living or participation

Exclusion Criteria:
  • Changes in spasticity medication during the last 3 months

  • Treatment with botulinum toxin during the last 6 months

  • Anticoagulant medication

  • Thrombosis

  • Malignant tumors

  • Pregnancy

  • Inflammations or skin lesions in the treated area

  • Acute urinary tract infection

  • Intended change in spasticity medication within 5 days after intervention

Contacts and Locations

Locations

Site City State Country Postal Code
1 Swiss Paraplegic Centre Nottwil LU Switzerland 6207

Sponsors and Collaborators

  • Swiss Paraplegic Centre Nottwil

Investigators

  • Principal Investigator: Michael Baumberger, Dr. med., Swiss Paraplegic Centre

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Swiss Paraplegic Centre Nottwil
ClinicalTrials.gov Identifier:
NCT02203994
Other Study ID Numbers:
  • 2014-07
First Posted:
Jul 30, 2014
Last Update Posted:
Jan 26, 2017
Last Verified:
Jan 1, 2017
Keywords provided by Swiss Paraplegic Centre Nottwil
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 26, 2017